In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...
Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes it a top stock to buy and hold for dividend investors -- arguably one of ...
The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...
The World Health Organization (WHO) has approved Abbott Molecular’s mpox diagnostic test, Alinity m MPXV assay, for emergency use. This first mpox in vitro diagnostic (IVD) listed under WHO’s ...
Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on ...
Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the beginning of Abbott's immunodiagnostics business. A year later, the Abbott Diagnostics Division was ...
Citi reaffirmed its positive stance on Abbott Laboratories (NYSE:ABT), maintaining a Buy rating and a price target of $127.00. The endorsement follows updates from the company's management regarding ...
Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Abbott appears a compelling earnings-beat candidate. However, investors should pay ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback